Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: A randomized controlled trial

Hepatobiliary and Pancreatic Diseases International

Volumn 2, Issue 2, 2003, Pages 211-215

  Pan, Ding Yu ^a   Qiao, Jian Guo ^a   Chen, Ji Wei ^a   Huo, Yin Cheng ^a   Zhou, Ya Kui ^a   Shi, Hai An ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Estrogen receptor; Hepatocellular carcinoma; Octretide; Randomized study; Tamoxifen

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ESTROGEN RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MITOMYCIN C; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD CELL COUNT; BONE MARROW DEPRESSION; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE FUNCTION TEST; IMMUNOGLOBULIN BLOOD LEVEL; INOPERABLE CANCER; LIVER CANCER; LIVER FUNCTION; LIVER TUMOR; MALE; METASTASIS; MOUTH ULCER; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; LIVER; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; OCTREOTIDE; TAMOXIFEN;

EID: 0038205509     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Villa E, Grottola A, Colantoni A. Hepatocellular carcinoma: role of estrogen receptors in the liver. Ann NY Acad Sci 2002;963:37-45.
2. Liu CL, Fan ST, Ng IO. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218-222.
3. Nagasue N, Yu L, Yukaya H. Androgen and estrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 1995;82:542-547.
4. Evans AA, Crook T, Laws S. Analysis of somatostatin receptor subtype MRNA expression in human breast cancer. Br J Cancer 1997;75:797-803.
5. Tomassettl P, Migliori M, Gullo L. Slow-Release canreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998;93:1468-1471.
6. Degen L, BegLinger C. The role of octreotide in the treatment of gastroenteropancreatic tumors. Regestion 1999;60(Suppl 2):(9-14.
7. Goldberg RM, Moertel CG, Wieand HS. A phase III evaluation somatostatin analogue ( octreotide ) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995;76:961-966.
8. Pallak MN, Schallg AV. Mechanism of antineoplastic action of somatostation analogs. Proc Soc Exp Bio Med 1998;217:1513-1521.
9. Zhang GJ, Kimijima I, Onda M. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-x (L), without alteration of P53 protein levels. Clin Cancer Res 1999;5: 2971-2977.
10. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in extrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res 1999;19:1657-1662.
11. Bernstein L, Depen D, Cerhan JR. Tamoxifen therapy for breast cancer and eudometrial cancer risk. J Natl Cancer Inst 1999;91:1654-1662.
12. Wang XB, Wang X, Zhang NZ. Somatosta and gastric carcinoma. World Chin J Digestol 2000;19:1185-1189.
13. Chen XJ, Ai ZL, Liu ZS. The antineoplastic mechanism of somatostatin analogs. Foreign Med Sci (Sections of Pathophysiology and Clinical Medicine) 2000; 13:82-90.
14. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinoid of a human breast carcinoma cell line in vitro and athymic mice. Cancer Res 1984;44:5757-5761.
15. SheiKh MS, Shao ZM, Li XS. Retinoid breast carcinoma cells transfected with RARα acquire sensitivity to growth inhibition by retinoids. J Biol Chem 1994; 169:1440.
16. Shao ZM, Yu LM, Jiang M. Inhibition of estrogen receptor-positive human breast carcinoma cell growth by retinoic acid. Chin J Oncol 1997;19:245-248.
17. Castells A, Bruix J, Bru C. Treatment of hepatocellular carcinoma with Tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109:917-922.
18. Manesis EK, Giannoulis G, Zoumboulis P. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-1542.
19. Kapadia CR. Somatostatin and hepatocellular carcinoma. Gastroenterology 1998;115:1298-1299.
20. Diaconu CC, Szathmari M, Keri G. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 1999;80:1197-1203.
21. Radulovics, Schally AV, Reile H. Inhibitory effects of antagonists of bombesinal/gastrin releasing peptide (GRP) and somatostatin anlong (RC-160) on growth of HT-29 human colon cancer in nude mice. Acta Oncol 1994;37:693-701.
22. Cascinus, Ferro ED, Catalano G. A randomized trial of octreotide vs best supportive care in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995;71:97-101.
23. Melen-Mucha G, Winczky K, Pawlikowski M. Somatostatin analogs octreotide and melatonin inhibit bromodeoxyuridine incorporation into cell nuclei and enhance apoptosis in the transplautable murine colon 38 cancer. Anticancer Res 1998;18:3615-3619.
24. Kouroumalis E, Skordilisp, Thermos K. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998;42:442-447.
25. Allgaier HP, Becker G, Blum HE. A therapeutic study of hepatocellular carcinoma using octreotide. Hepatocellular carcinoma: treatment with octreotide. Dtsch Med Wochenschr 2000;125:320.
26. Chen XJ, Liu ZS, Ai ZL. Antineoplastic mechanism of octreotide action in human hepatoma. Chin Med J 2001;114:1167-1170.
27. Melia WM, Johnson PJ, Williams R. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treatment Reports 1987;12:1213.
28. Duet M, Ajzerberg C, Benelhadj S. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo. J Nucl Med 1999; 40:1252-1256.
29. Denzler B, Reibi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999;85:188-198.
30. Reubi JC, Zimmermann A, Jonas S. Regulatory peptide receptors in human hepatocellular carcinoma. Gut 1999;45:766-774.
31. Trangarajn M, Shamak L. Interdependent regulation of intracellar accidification and SHP-1 in apoptosis. Cancer Res 1999;59:1649-1654.
32. Devies N, Kgnaston H, Yates J. Octreotide, the reticuloendothelial system and experimental liver tumor. Gut 1995;36:610-614.